Molecular Breast Imaging Market Size, Share, Clinical Adoption Trends and Forecast, 2026–2035

Molecular Breast Imaging Market Overview

The global molecular breast imaging market was valued at USD 612 million in 2025 and is forecast to reach USD 1.15 billion by 2035, expanding at a CAGR of 6.5% during 2026–2035. Growth is supported by the need for supplementary evaluation in women with dense breast tissue, wider awareness of functional imaging, lower-dose detector development and demand for alternatives when magnetic resonance imaging is inaccessible, contraindicated or poorly tolerated.

Molecular breast imaging (MBI) is a nuclear-medicine technique that images radiotracer uptake rather than breast anatomy alone. A patient receives an intravenous gamma-emitting tracer, most commonly technetium-99m sestamibi. A dedicated gamma camera images the breast under light immobilization. Tissue with increased metabolic or mitochondrial activity may show higher tracer uptake, helping clinicians investigate suspicious findings that are difficult to characterize with conventional structural imaging.

MBI is also called breast-specific gamma imaging or scintimammography, although equipment design and clinical terminology vary. The market in this report includes dedicated single- and dual-detector breast gamma cameras, breast-procedure use of relevant radiopharmaceuticals, image-processing software, maintenance and application support. It excludes general mammography, digital breast tomosynthesis, automated breast ultrasound, contrast-enhanced mammography, MRI, PET and surgical gamma probes. Those technologies are discussed only where they compete for the same supplementary imaging decision.

The market remains specialized. Mammography is the primary population-screening platform in most health systems, while ultrasound, MRI and contrast-enhanced mammography have broader installed bases. In the United States, Curium’s technetium-99m sestamibi labeling states that planar breast imaging is a second-line diagnostic use after mammography for evaluating a breast lesion following an abnormal mammogram or palpable mass. It is not labeled as a breast-cancer screening drug, does not confirm or exclude malignancy and does not replace biopsy. Commercial claims must distinguish clinical research, local practice and approved labeling.

Key Highlights

• Dedicated imaging systems generated 54% of 2025 revenue, equal to USD 330 million, including breast-specific gamma cameras and integrated acquisition workstations.
• Dual-head cameras held 61% of modality revenue, or USD 373 million, because opposing detectors can improve proximity, count sensitivity and lesion localization.
• Diagnostic and problem-solving applications represented 58%, equivalent to USD 355 million, exceeding supplementary screening use.
• Hospitals accounted for 46% of market revenue, or USD 282 million, supported by nuclear-medicine licensing, radiopharmacy access and multidisciplinary breast services.
• North America led with 40.3% of global revenue, equal to USD 247 million, while the United States alone contributed 36.5%, or USD 223 million.
• Asia-Pacific held 24%, or USD 147 million, and is expected to post the fastest regional growth through 2035.
• Commercial adoption depends on referral criteria, radiation-dose protocols, tracer logistics, reimbursement and evidence that MBI changes patient management.

Strategic Takeaways

• Define MBI as targeted supplementary imaging, not a universal mammography replacement.
• Prioritize dense-breast and MRI-ineligible diagnostic pathways.
• Pair camera placement with dependable technetium-99m and sestamibi access.
• Prove management impact, not detection sensitivity alone.
• Reduce administered activity without weakening lesion visualization.
• Build referral protocols jointly with radiology and nuclear medicine.
• Keep regulatory labeling separate from research-led screening claims.

Market Dynamics

Dense breast tissue creates a clinically important detection gap

Dense fibroglandular tissue can obscure cancer on mammography because both appear radiopaque. Density is also an independent risk factor for breast cancer. The combination creates demand for supplementary modalities that offer a different signal. MBI is less affected by tissue density because it measures radiotracer uptake. This creates a defined clinical proposition in women whose mammograms are negative, equivocal or difficult to interpret, provided the examination is appropriate under local guidance and labeling.

Competition for that supplementary exam is intense. Ultrasound avoids ionizing radiation and is widely available but can be operator-dependent and generate false-positive findings. MRI offers high sensitivity but has higher capital and examination costs, longer scan times, contrast considerations and access limitations. Contrast-enhanced mammography fits familiar mammography workflows but uses iodinated contrast and x-ray exposure. MBI competes best where functional information, patient tolerance, installed nuclear-medicine capability and local expertise create a practical advantage.

Detector engineering determines dose and workflow competitiveness

The earlier generation of scintimammography used general gamma cameras that could not approach the chest wall closely. Dedicated breast systems use compact detectors and breast positioning similar to mammography. Cadmium-zinc-telluride detectors convert gamma photons directly into electrical signals and can support improved energy resolution and compact geometry. Sodium iodide systems offer an established and potentially lower-cost route but may differ in detector thickness, resolution and portability.

Dual-head cameras image opposing sides of the breast at the same time. This can improve sensitivity and reduce the distance between a lesion and at least one detector. Single-head systems can provide portability and a smaller capital commitment. Purchasing decisions depend on administered activity, examination time, detector field of view, dead space at the chest wall, count sensitivity, image reconstruction, positioning, service coverage and compatibility with biopsy or localization workflows.

Tracer supply is part of the equipment business case

An MBI camera cannot generate procedure revenue without reliable technetium-99m and sestamibi supply. Technetium-99m has a short physical half-life and is commonly obtained from molybdenum-99/technetium-99m generators or regional radiopharmacies. Interruptions at isotope-production reactors, processing sites or transport networks can affect procedure scheduling. The sestamibi kit must be prepared under radiopharmacy controls and used within its labeled time window.

This makes market access different from conventional breast-imaging equipment. A vendor must assess the institution’s radioactive-material license, hot-lab capability, technologist staffing, dose handling, waste processes and tracer-delivery radius before forecasting utilization. Facilities with established cardiac nuclear medicine may have infrastructure in place, but breast scheduling still needs dedicated protocols and coordination.

Radiation dose and screening policy remain adoption constraints

MBI exposes the whole body to ionizing radiation from an injected radiopharmaceutical. Modern low-dose protocols can reduce administered activity compared with older approaches, but the exposure profile differs from mammography because the tracer distributes beyond the breast. This issue is especially important when evaluating repeated screening in asymptomatic women. Health systems need a clear risk-benefit rationale based on age, breast density, cancer risk, prior findings and available alternatives.

The distinction between diagnostic evaluation and screening is commercially decisive. A center may find a defensible use for problem solving after an abnormal mammogram, evaluation of disease extent, assessment of treatment response or imaging when MRI cannot be performed. Building a large population-screening program requires a higher evidence and policy threshold. Overstating the screening indication creates clinical, regulatory and reimbursement risk.

Reimbursement and throughput shape capital purchasing

MBI requires a camera, radiotracer, radiopharmacy handling, technologist time, physician interpretation and room capacity. A capital proposal must compare incremental cancer detection and avoided downstream testing with the full procedure cost. Low daily volume weakens equipment utilization, while long acquisition protocols limit throughput. Hospitals may prefer shared nuclear-medicine assets if breast volume is uncertain, but dedicated cameras deliver better breast positioning and lesion proximity.

Revenue growth therefore depends less on broad awareness than on complete referral pathways. A viable program identifies eligible patients, schedules tracer delivery, performs the exam efficiently, integrates results into breast conferences and tracks biopsy or treatment outcomes. Evidence showing that MBI resolves indeterminate findings or prevents more expensive examinations can strengthen payer discussions.

Market Scope and Forecast

Market Segmentation Analysis

By Component

Dedicated imaging systems led with 54% of 2025 market revenue, or USD 330 million. This category includes breast-specific gamma cameras, detector heads, positioning assemblies and acquisition workstations. Its large share reflects capital-equipment pricing and the concentration of suppliers. Replacement demand remains limited because the installed base is small and systems have long service lives; growth depends mainly on new placements and upgraded low-dose detector configurations.

Radiopharmaceuticals accounted for 34%, equal to USD 208 million. The segment includes the breast-procedure share of technetium-99m sestamibi and related preparation economics, not the molecule’s much larger cardiac-imaging use. Recurring per-procedure demand gives this segment stronger continuity than equipment sales. Supply security, generator economics and labeled use shape regional access.

Software, maintenance and clinical services represented 12%, or USD 73 million. This includes image processing, workstation support, service contracts, quality assurance, installation and application training. The segment can grow faster as vendors add remote support, structured reporting, dose tracking and AI-assisted interpretation, but algorithms need modality-specific clinical validation.

By Modality

Dual-head gamma cameras generated 61% of 2025 revenue, equivalent to USD 373 million. Their opposing detector geometry supports close breast contact and improved count collection. These systems suit higher-volume centers that value image quality, lower-dose potential and a mammography-like acquisition approach. Their drawbacks include higher capital cost, larger footprint and more complex servicing.

Single-head cameras held 39%, or USD 239 million. Portability, lower acquisition cost and simpler room requirements support use in smaller centers and diagnostic practices. Single-detector systems must compete through positioning, detector sensitivity and acquisition efficiency because lesion distance can affect image quality. The segment remains relevant where a dual-head purchase cannot be justified by procedure volume.

By Application

Diagnostic and problem-solving imaging accounted for 58% of 2025 revenue, equal to USD 355 million. Use cases include evaluation following an abnormal mammogram or palpable finding, investigation of indeterminate conventional imaging, assessment of disease extent, recurrence evaluation and cases in which MRI is unsuitable. This segment benefits from a clearer immediate clinical question and is generally easier to defend than routine screening.

Supplementary breast screening represented 42%, or USD 257 million. Dense-breast awareness and risk-stratified imaging support interest, but adoption varies significantly because radiation exposure, labeling, payer policies and alternative modalities differ by country. The segment forecast assumes selective use in defined higher-risk or difficult-to-image groups, not replacement of population mammography.

By End User

Hospitals led with 46% of 2025 revenue, or USD 282 million. They combine nuclear-medicine infrastructure, breast radiology, oncology, surgery and pathology, allowing MBI findings to feed directly into multidisciplinary care. Diagnostic imaging centers accounted for 31%, equal to USD 190 million, but participation depends on isotope licensing and sufficient breast volume.

Specialty breast clinics held 15%, or USD 92 million. These centers can build focused dense-breast pathways and a patient-centered experience, yet many lack a radiopharmacy. Academic and research institutions represented the remaining 8%, or USD 49 million. Their value extends beyond revenue because they generate protocol, dose, comparative-effectiveness and outcomes evidence needed for wider adoption.

Regional and Country-Level Analysis

North America

North America generated 40.3% of global 2025 revenue, equal to USD 247 million. The United States contributed 36.5%, or USD 223 million, supported by dense-breast notification, established nuclear medicine, specialized breast centers and domestic MBI suppliers. Adoption remains institution-specific because payer coverage, tracer labeling and local clinical policy vary. Canada represented 3.8%, or USD 23 million, where provincial technology assessment and centralized hospital purchasing moderate uptake.

Europe

Europe held 27%, equivalent to USD 165 million. Germany contributed 6% of global revenue, or USD 37 million, reflecting a large diagnostic-imaging base and nuclear-medicine expertise. The United Kingdom and France each represented 4%, or USD 24 million. Italy held 3%, or USD 18 million, while Spain accounted for 2.5%, or USD 15 million. The rest of Europe generated 7.5%, or USD 46 million. MRI and contrast-enhanced mammography provide strong competition, so MBI growth depends on carefully selected indications and local reimbursement.

Asia-Pacific

Asia-Pacific represented 24% of the market, or USD 147 million, and is expected to expand fastest through 2035. Japan held 6% of global revenue, equal to USD 37 million, supported by advanced imaging infrastructure and an aging population. China generated 5%, or USD 31 million, with opportunity concentrated in major oncology and tertiary hospitals. South Korea accounted for 3%, or USD 18 million, and India held 2.5%, or USD 15 million. Australia and the remaining regional markets contributed 7.5%, or USD 46 million. Limited dedicated-camera availability and isotope logistics remain major barriers outside large cities.

Latin America

Latin America accounted for 5% of 2025 revenue, equal to USD 31 million. Brazil represented 2.2% of the global market, or USD 13 million, while Mexico held 1.2%, or USD 7 million. The rest of the region generated 1.6%, or USD 10 million. Private cancer centers and urban nuclear-medicine networks provide the main commercial route. Currency exposure, capital budgets and uneven tracer access restrict wider placement.

Middle East and Africa

The Middle East and Africa held 3.7%, or USD 23 million. Saudi Arabia and the United Arab Emirates together contributed 1.5% of global revenue, or USD 9 million, supported by investment in tertiary care. South Africa accounted for 0.7%, or USD 4 million. The remaining markets generated 1.5%, or USD 9 million. Scarce breast-imaging specialists, limited isotope distribution and competing priorities constrain demand, although major oncology centers can support targeted installations.

Competitive Landscape

The dedicated MBI equipment field is narrow and differs from the broader breast-imaging industry. SmartBreast markets systems derived from previously established GE HealthCare and Dilon platforms. Dilon remains an important historical participant in breast-specific gamma imaging but its current public product portfolio emphasizes surgical and specimen technologies. Curium participates through technetium-99m sestamibi rather than camera hardware. General nuclear-medicine camera companies and breast-imaging leaders influence purchasing alternatives even when they do not sell a dedicated MBI unit.

Competition centers on detector performance, administered activity, breast positioning, service continuity, installed-base support and the ability to build a complete clinical program. A camera vendor without tracer logistics or referral development faces slow utilization. A radiopharmaceutical supplier benefits from procedure growth but must keep breast-use revenue separate from dominant cardiology demand.

Key Players

SmartBreast Corporation; CMR Naviscan Corporation; Dilon Technologies, Inc.; Curium Pharma; GE HealthCare Technologies Inc.; Digirad Corporation; Spectrum Dynamics Medical; Siemens Healthineers AG; and MiE GmbH.

Company Profiles

SmartBreast Corporation

SmartBreast focuses directly on molecular breast imaging through the Eve Clear Scan portfolio. The e750 uses dual-detector cadmium-zinc-telluride technology designed for close chest-wall positioning, while the e680 uses a portable single-detector sodium iodide architecture. The company acquired rights to systems associated with GE HealthCare’s Discovery NM 750b and Dilon’s D6800 and established a manufacturing relationship with FoxSemicon Integrated Technologies. Its competitive advantage is a dedicated MBI proposition rather than a broad imaging portfolio. Commercial success depends on installed-base service, evidence generation, dose optimization and access to breast centers able to operate nuclear-medicine workflows.

Curium Pharma

Curium supplies technetium-99m generators and a generic kit for preparing technetium Tc-99m sestamibi injection. In the United States, the product is labeled for planar imaging as a second-line diagnostic drug after mammography to assist in evaluating breast lesions in patients with an abnormal mammogram or palpable mass. The label states that it is not indicated for breast-cancer screening, does not confirm or rule out malignancy and is not an alternative to biopsy. Curium’s role is strategically important because recurring tracer availability determines whether installed MBI capacity can be used. In June 2026, the company announced an investment exceeding EUR 32 million at its Saclay, France operation; the announcement covered broader radiopharmaceutical capacity and was not presented as MBI-specific production.

Dilon Technologies, Inc.

Dilon commercialized the Dilon 6800 breast-specific gamma imaging platform and helped establish the dedicated gamma-camera category. Its current public portfolio emphasizes MarginProbe for intraoperative margin assessment, Navigator for radioguided localization, TrueView specimen radiography and other medical devices. SmartBreast identifies its e680 as derived from the Dilon platform. Dilon should therefore be viewed as a legacy technology owner and breast-care participant rather than assumed to be actively marketing a new dedicated MBI camera under the historic product name. Its breast-surgery relationships and gamma-probe knowledge remain relevant to integrated cancer-care pathways.

GE HealthCare Technologies Inc.

GE HealthCare historically supplied the Discovery NM 750b dedicated MBI system, whose technology is represented in SmartBreast’s e750 platform. GE HealthCare’s current breast-imaging strategy publicly emphasizes mammography and automated breast ultrasound, while its wider business includes molecular imaging and pharmaceutical diagnostics. In August 2026, it launched Invenia ABUS Prime and ABUS StreamVue for supplemental dense-breast imaging. These are ultrasound products, not MBI, but they compete for the same dense-breast workflow and capital budget. GE HealthCare’s importance to this market is therefore both historical and competitive: its legacy detector platform supports current MBI offerings, while its active portfolio provides an alternative modality.

Recent Developments

• August 2026 – GE HealthCare: The company launched Invenia ABUS Prime and ABUS StreamVue following U.S. FDA clearance and CE marking. The products are automated breast ultrasound, not MBI. Their relevance is direct competition for supplemental dense-breast imaging budgets and multi-site reading workflows.
• June 2026 – Siemens Healthineers: The U.S. FDA cleared contrast-enhanced mammography and contrast-enhanced biopsy capabilities for Mammomat B.brilliant. This is not molecular breast imaging. It expands a competing functional breast-imaging pathway for dense tissue and indeterminate findings.
• June 2026 – Curium Pharma: Curium announced an investment exceeding EUR 32 million at Saclay, France. The investment supports broader radiopharmaceutical capabilities and supply resilience; the company did not describe it as dedicated to technetium-99m sestamibi for breast imaging.
• April 2026 – Hologic: Hologic presented evidence on AI-assisted detection of challenging breast cancers using mammography and tomosynthesis. The development concerns mammographic AI rather than MBI but affects the threshold at which supplementary imaging is requested.
• April 2026 – Lunit: Lunit reported deployment of its breast-imaging AI ecosystem across more than 330 sites in the Americas and one million annual screening examinations, alongside FDA clearance of an updated 3D mammography algorithm. The announcement is adjacent competitive intelligence, not an MBI launch.

Molecular Breast Imaging Market Overview

Global molecular breast imaging market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period 2023-2030.

Molecular breast imaging also known as scintimammography, nuclear medicine breast imaging and breast-specific gamma imaging, is an advanced and FDA-approved imaging technology that is used to identify breast cancer in women with dense breast tissue. Molecular breast imaging uses a special camera and a small amount of radioactive tracer to spotlight differences in tissue activity and differentiate healthy, dense tissue from breast irregularities. It is a highly accurate imaging study with a low chance of missing cancerous cells. 

Moreover, a small amount of radioactive tracer is administered to the patient through an intravenous line. The tracer is swiftly absorbed by rapidly dividing cells, including cancer cells, and appears highlighted on imaging results. The patient places her breast on a special platform which is similar to that of a mammogram machine. The breast is gently compressed to capture high-quality images with a special gamma camera, but this light compression should not cause discomfort. The gamma cameras record the breast’s tissue activity for about 20 minutes.

Molecular Breast Imaging Market Scope

For more details on this report Request for Sample

Molecular Breast Imaging Market Dynamics: Drivers

Increasing adoption of molecular breast imaging for breast cancer screening 

The increasing adoption of molecular breast imaging for breast cancer screening is expected to drive the market over the forecast period. Molecular breast imaging is known for its higher sensitivity in detecting breast cancer, particularly in women with dense breast tissue. It can help identify tumors that might be missed by mammography alone. This increased accuracy is a significant driver of its adoption.

Moreover, molecular breast imaging is often used as a complementary screening tool alongside mammography. Also, in cases where the mammograms yield inconclusive results or when additional information is needed, this imaging technique can provide valuable insights by reducing the risk of missed or delayed cancer diagnoses. 

Ongoing advancements in this imaging technology have made it more accessible and easier to use. These technological improvements like the development of digital gamma cameras and more comfortable imaging procedures, make it a more attractive option. It is often recommended for high-risk patients such as those with a family history of breast cancer or known genetic mutations like BRCA1 and BRCA2. The ability to detect cancer at an earlier stage can be lifesaving for these individuals.

For instance, on February 9, 2021,  SmartBreast Corporation released that it has formed a partnership with FoxSemicon Integrated Technologies, Inc. (FITI) to manufacture Molecular Breast Imaging (MBI) systems. FITI has invested substantially in SmartBreast and will be the contract manufacturer for two MBI systems recently acquired by SmartBreast, the GE Healthcare Discovery NM 750b and the Dilon Technologies D6800. SmartBreast will rebrand the two systems as EVE CLEAR SCAN e750 and e680, respectively. Together, SmartBreast and FITI will co-develop and manufacture innovative, cost-effective, next-generation MBI systems to further increase the efficacy of detecting cancer in the earlier stage and to increase the adoption. 

Further, the increasing prevalence of breast cancers, rising FDA approvals for novel and advanced molecular imaging techniques for breast, increasing clinical trials to develop more advanced devices, increasing awareness and advancements in the development of molecular breast imaging devices are the factors expected to drive the market over the forecast period.

Restraints

Factors such as complications associated with molecular breast imaging,  the high cost of associated with this imaging technique, this test can't detect all cancers and the tracer in the molecular breast imaging can develop allergic reactions are expected to hamper the market. 

Molecular Breast Imaging Market Segmentation

The global molecular breast imaging market is segmented based on design type, modality, application, end-user and region.

The gamma camera segment accounted for approximately 45.3% of the molecular breast imaging market share

The gamma camera segment is expected to hold the largest market share over the forecast period. The gamma camera in molecular breast imaging is mainly responsible for capturing images of the breast tissue after the injection of a radioactive tracer. It detects gamma rays emitted from the tracer, which is preferentially taken up by areas with increased metabolic activity, such as breast cancerous tumors.

Furthermore, the sensitivity of the gamma camera is crucial in detecting even small or low-activity tumors in the breast. This molecular breast imaging which consists of the gamma camera offers another option for women to be proactive about their breast health. Modern gamma cameras are designed for efficiency by allowing for quicker image acquisition and reduced radiation exposure for patients. Efficiency is a vital consideration, as it impacts patient comfort.

Additionally, the gamma cameras of molecular breast imaging often come equipped with advanced image processing and analysis software. These tools aid radiologists in interpreting the images, making the camera an integral part of the diagnostic process. The design and functionality of the gamma camera can significantly influence the patient's experience. A comfortable and well-designed camera can help reduce anxiety and improve the overall patient experience during the molecular breast imaging procedure.

Global Molecular Breast Imaging Market Geographical Share

North America accounted for approximately 40.3% of the market share 

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and increasing research activities. North America especially the United States is a hub for its strong presence of major players such as diagnostic companies and medical device companies. The presence of major players actively focusing on the development of more advanced molecular breast imaging by the technological advancements for better adoption along with better patient outcomes.

Furthermore, the increasing prevalence of breast cancer in the region is very high, which is considered to drive the market in the region. Due to the high prevalence of breast cancer in the region, it is known for the increased adoption for the diagnosis and screening of breast cancer. Early detection reduces the death rate of the patients by early detection and diagnosis.  

For instance, according to the National Institute of Health (NIH), 2021, in the United States, there are over 250,000 new cases of breast cancer annually with over 46,000 women dying of the disease. Over the past two decades, the death rate from breast cancer has decreased by over 40%, a monumental achievement, due to the combination of improved detection as well as improved, increasingly targeted therapies. When breast cancer is detected early, over 95% of women survive more than five years.

Molecular Breast Imaging Companies

The major global players in the molecular breast imaging market include CMR Naviscan Corporation, SmartBreast Corporation and DIGIRAD HEALTH, INC. among others. 

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global molecular breast imaging market. During the pandemic, molecular breast imaging procedures are postponed or canceled temporarily due to the redirected focus on the pandemic and its associated risks. Molecular breast imaging experienced a drop in patient volumes as people postponed routine visits. The pandemic disrupted supply chains for the components and materials needed for molecular breast imaging systems. Delays in the manufacturing and distribution of these components affected the availability of these imaging equipment.

Why Purchase the Report?

• To visualize the global molecular breast imaging market segmentation based on design type, modality, application, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of molecular breast imaging market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global molecular breast imaging market report would provide approximately 48 tables, 59 figures, and 187 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies